Ocrelizumab is a medicine used to treat multiple sclerosis (MS). It is given as an infusion into a vein every few months, or as a shot under the skin. It works by lowering certain immune cells, called B cells, that attack the nerves in MS.
Every report comes from a Lived member, sent anonymously.
Have you tried Ocrevus (Ocrelizumab) for MS (Multiple Sclerosis)?
Ocrelizumab is a long-term prescription treatment for multiple sclerosis (MS), a disease in which the immune system damages the brain and spinal cord. It comes in two forms: Ocrevus, given as an infusion into a vein, and Ocrevus Zunovo, given as an injection under the skin. In adults, both forms are approved for relapsing forms of MS and for primary progressive MS. Relapsing MS includes clinically isolated syndrome (a first MS-like episode), relapsing-remitting MS, in which flare-ups are followed by periods of recovery, and active secondary progressive MS, in which disability builds steadily but flare-ups or new inflammation still occur. Primary progressive MS worsens gradually from the start without clear flare-ups. The infusion form, Ocrevus, is also approved for children 10 and older who weigh at least 25 kg (about 55 pounds) and have relapsing-remitting MS. Ocrevus Zunovo is approved for adults only. Ocrelizumab is a disease-modifying therapy: its purpose is to prevent new inflammation and slow the course of MS, not to relieve symptoms such as fatigue, stiffness or bladder problems from day to day.
MS damages myelin, the protective coating around nerve fibers, which slows or blocks the signals traveling between the brain and the body. B cells, a type of white blood cell that makes antibodies and helps direct other immune cells, are thought to play a central part in this attack. Ocrelizumab is a monoclonal antibody, a lab-made protein designed to lock onto one specific target. Its target is CD20, a marker found on the surface of most B cells. Once it attaches, the body's own defenses destroy those cells, and B cell counts in the blood fall within about two weeks. A dose every six months keeps them low. Exactly why this calms MS is not fully understood, but in trials it sharply reduced the new areas of inflammation that show up on MRI scans. The effect lasts well beyond each dose. After the last dose, B cells take a long time to return: in one study, half of adults were back to normal levels by about 72 weeks, and 90% within two and a half years.
Both forms are given by a health care professional in a clinic or infusion center. Before the first dose, blood tests check for hepatitis B, antibody (immunoglobulin) levels and liver function. Vaccines are ideally brought up to date beforehand: live vaccines at least 4 weeks before starting, and other vaccines at least 2 weeks before when possible. Before every dose, the team asks about infections, because a dose is postponed until an active infection has cleared. With Ocrevus, the IV form, treatment starts with two half doses given two weeks apart, each infusion lasting about two and a half hours or longer. After that, one full infusion is given every six months. It runs about three and a half hours, or about two hours for people who have not had a serious reaction to an earlier infusion. Children's doses are based on weight. A steroid and an antihistamine are given before each infusion to reduce the chance of a reaction, and people are watched for at least an hour afterward, so an infusion visit is a long appointment. Ocrevus Zunovo is injected under the skin of the abdomen over about 10 minutes every six months. An oral steroid and antihistamine are taken at least 30 minutes beforehand. People are observed for at least an hour after the first injection and at least 15 minutes after later ones. The two forms use different doses, so one should not be swapped for the other without the prescriber's direction. If a dose is missed, it should be given as soon as possible rather than at the next planned date, and the schedule then resets to six months from that dose. Doses must be at least five months apart.
Infusion reactions are the most common problem. In adult trials, about a third or more of people had one, most often with the first infusion. Signs include itching, rash, hives, flushing, throat irritation, headache, fever, dizziness, nausea and a fast heartbeat. During the infusion, the team usually manages them by slowing or pausing the drip and giving medicine. Reactions can also start up to 24 hours later, so contact the care team right away if these signs appear after leaving the clinic. Trouble breathing, swelling of the throat, or feeling faint is a severe reaction: call 911. With Ocrevus Zunovo, about half of people had a reaction to the first injection, usually redness, pain, swelling or itching at the injection site, sometimes with headache or nausea. Because ocrelizumab lowers part of the immune system, infections are more common. Most are mild to moderate: colds and other upper respiratory infections, bronchitis, skin infections, and herpes outbreaks such as cold sores and shingles. Contact the care team about fever, chills, a cough that won't go away, painful urination, or new cold sores, shingles or genital sores, during treatment or after the last dose. Herpes infections occasionally spread to the eyes or the brain. Eye pain or redness, worsening vision, a headache with a stiff neck, or confusion needs prompt contact with the care team. Other effects reported somewhat more often than with comparison treatments include depression, back pain, pain in the arms or legs, cough, diarrhea and swelling in the legs.
Ocrelizumab is not used in people with an active hepatitis B infection, or in anyone who has had a life-threatening reaction to it. In people who carry hepatitis B or had it in the past, it can reawaken the virus and cause serious liver damage, which is why everyone is tested first and a liver specialist is involved when the test shows a past infection. Liver injury has also been reported without hepatitis, weeks to months after a dose. Unusual tiredness, loss of appetite, nausea or vomiting, pain in the upper right abdomen, dark urine, or yellowing of the skin or eyes should be reported promptly. Progressive multifocal leukoencephalopathy (PML) is a rare brain infection caused by the JC virus that usually leads to death or severe disability. It has been reported with ocrelizumab, including in people with no other known risk factors. Its signs build over days to weeks: weakness on one side of the body that keeps getting worse, clumsiness, vision changes, or changes in thinking, memory or personality. Because these can look like an MS relapse, they need prompt contact with the neurologist. Immune-mediated colitis, an inflammation of the bowel, can appear weeks to years into treatment and is sometimes severe. New or persistent diarrhea, abdominal pain, or blood in the stool should be reported promptly. Antibody levels can fall over time, and low levels are linked to more serious infections, so they are checked with blood tests. Ocrelizumab may also raise cancer risk: in trials, breast cancer occurred in 6 of 781 women taking it and none of 668 women on comparison treatments, so routine breast cancer screening matters. Other medicines that suppress the immune system, including high-dose steroids, add to infection risk. Switching from MS medicines with long-lasting immune effects, such as fingolimod, natalizumab or teriflunomide, needs careful timing for the same reason. Live vaccines are not recommended during treatment or until B cells have recovered. Non-live vaccines, such as the flu shot, can be given but may produce a weaker response. People who could become pregnant should use effective contraception during treatment and for 6 months after the last dose, and should tell the care team if a pregnancy is planned or occurs. Babies exposed before birth may have low B cell counts, which affects the timing of their own live vaccines. Little is known about ocrelizumab in breast milk, so breastfeeding is a decision to make with the care team.
Ocrelizumab works over months and years rather than from one day to the next. Apart from possible side effects, most people notice little directly after a dose. Success means fewer relapses, fewer new areas of inflammation on MRI, and slower buildup of disability. In two trials of relapsing MS, it cut the yearly relapse rate roughly in half compared with interferon beta-1a (Rebif), an older injected MS medicine. Over about two years, 82 to 83% of people taking ocrelizumab had no relapse, compared with 71 to 72% on interferon, and confirmed worsening of disability occurred in about 10% versus 15%. In primary progressive MS the benefit is smaller: over at least two years, disability worsened in about 33% of people taking ocrelizumab compared with 39% on placebo. It can slow progression, but it does not stop it or reverse damage already done. Treatment settles into a rhythm of a dose every six months, regular neurology visits, and blood tests for antibody levels and, when needed, liver function. A new relapse or new inflammation on MRI while on treatment is a reason to review the plan with the neurologist. Because B cells stay low for a long time, the immune effects and infection risk can last many months after the last dose, which matters when planning a pregnancy, vaccines or a switch to another medicine. How long to continue is decided individually with the neurologist.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Ocrevus (Ocrelizumab), what you've noticed, or ask the community a question.